Clinical Trials
3 trialsNCT03625323 2026-04-22
TACTI-002
Immutep S.A.S.
Phase 2 Completed
NCT06726265 2026-03-18
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
Immutep S.A.S.
Phase 3 Active not recruiting
NCT04811027 2025-12-11
TACTI-003
Immutep S.A.S.
Phase 2 Completed